Galectin Therapeutics Inc.

06/11/2025 | Press release | Distributed by Public on 06/11/2025 16:25

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
CZIRR JAMES C
2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [GALT]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
4908 S. ASHTON CT.
3. Date of Earliest Transaction (Month/Day/Year)
02/03/2025
(Street)
SPOKANE,, WA 99223
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/03/2025 G V 10,000 D (3) 731,416 D
Common Stock 02/04/2025 G V 10,000 D (3) 721,416 D
Common Stock 03/31/2025 J(1)(2) V 1,000 A $6(1) 722,416 D
Common Stock 06/06/2025 M 31,250 A $0.89 753,666 D
Common Stock 06/06/2025 M 46,875 A $2.39 800,541 D
Common Stock 06/06/2025 M 25,000 A $4.72 825,541 D
Common Stock 06/06/2025 M 30,000 A $2.86 855,541 D
Common Stock 06/06/2025 M 40,000 A $2.11 895,541 D
Common Stock 06/06/2025 M 70,000 A $2.11 965,541 D
Common Stock 06/06/2025 M 40,000 A $1.98 1,005,541 D
Common Stock 06/06/2025 M 40,000 A $1.11 1,045,541 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $0.89 06/06/2025 M 31,250 (4) 06/07/2025 Common Stock 31,250 $ 0 291,875 D
Stock Option (right to buy) $2.39 06/06/2025 M 46,875 (4) 06/07/2025 Common Stock 46,875 $ 0 245,000 D
Stock Option (right to buy) $4.72 06/06/2025 M 25,000 (4) 06/07/2025 Common Stock 25,000 $ 0 220,000 D
Stock Option (right to buy) $2.86 06/06/2025 M 30,000 (4) 06/07/2025 Common Stock 30,000 $ 0 190,000 D
Stock Option (right to buy) $2.11 06/06/2025 M 40,000 (4) 06/07/2025 Common Stock 40,000 $ 0 150,000 D
Stock Option (right to buy) $2.11 06/06/2025 M 70,000 (4) 06/07/2025 Common Stock 70,000 $ 0 80,000 D
Stock Option (right to buy) $1.98 06/06/2025 M 40,000 (4) 06/07/2025 Common Stock 40,000 $ 0 40,000 D
Stock Option (right to buy) $1.11 06/06/2025 M 40,000 (4) 06/07/2025 Common Stock 40,000 $ 0 0 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
CZIRR JAMES C
4908 S. ASHTON CT.
SPOKANE,, WA 99223
X

Signatures

/s/ James C. Czirr, Individually 06/11/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was paid on 3/31/2025. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend.
(2) Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9.
(3) No consideration was received for the shares, which were transferred by gift to relatives.
(4) Stock options were exercisable at time of exercise.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Galectin Therapeutics Inc. published this content on June 11, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 11, 2025 at 22:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io